Nathan Goodyear, MD, MD(H)

Nourish the body. Support the gut. Lower inflammation. Build resilience.

@benmckee14 @ALLVOLNEWS Love that guy. Such wisdom.

Nate Ament: "It's one of the reasons I chose Tennessee because of Coach Barnes and his faith. ... as a team, you're trying to glorify something bigger than yourself. And, ultimately, something that is Jesus Christ and is God can only lead to good things. When you're playing for something other than your own glory and the glory of others, the glory of your teammates, the glory of Christ, only good things can happen from there if you're being selfless and trying to take care of each other."

Full Video: x.com/jasonwilliamsm…

Check out this 2025 study on CD40: Juan C. Osorio, David A. Knorr, Polina Weitzenfeld, Lucas Blanchard, Ning Yao, Maria Baez, Carlo Sevilla, Meghan DiLillo, Jahan Rahman, Ved P. Sharma, Jacqueline Bromberg, Michael A. Postow, Charlotte Ariyan, Mark E. Robson, Jeffrey V. Ravetch. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell, 2025; 43 (10): 1902 DOI: 10.1016/j.ccell.2025.07.013

CD40 is a stimulatory agent, not a checkpoint inhibitor. Rather than releasing the brakes on an existing immune response, it helps recruit and activate multiple immune cell types at the tumor site. That is a critical distinction because checkpoint inhibitors are limited when the immune system is not already engaged. The reason intratumoral delivery matters here is that CD40 receptors are expressed across many healthy tissue types. Systemic delivery has consistently run into off-target toxicity. Putting it directly in the tumor concentrates the activation where it is needed.

@naturednurse Not fear: pushing through to hope.

@drgoodyear Fear keeps people stuck, confidence in restoration opens the door to real healing. Appreciate the clarity tho

The goal isn’t fear of toxins. The goal is confidence in restoration.

@TheRealDeeNice @jasonwilliamsmd Will be reposting soon.

@jasonwilliamsmd @drgoodyear Where can we fi d the recording. Family member has pancreatic cancer and brain cancer.

The FDA issued a warning letter to ImmunityBio over claims that Anktiva can "cure cancer" and "treat all cancers." There's a lot to unpack here. Today at 3:10 PM PST, @drgoodyear and I are going live to talk about what Anktiva actually is, how we use it at WCI, and why no single drug is the answer. Join us.

Glyphosate exposure may be common—but so is the body’s ability to repair when supported properly.

Anktiva, the FDA, and What Patients Need to Know 🚨 x.com/i/broadcasts/1…

Absolutely. I've written about Anktiva and IL-15 activation in my upcoming book. The science is solid. Where it gets interesting is what happens when you combine it with other agents directly in the tumor microenvironment. I'd welcome that conversation with Dr. Soon-Shiong any time.

Great breakdown on the Anktiva situation. You clearly see the potential in IL-15 activation and @DrPatrick work. Have you ever considered reaching out to him about combining Anktiva with your intratumoral approach? Feels like you two could do something significant together.

@PSea17 @jasonwilliamsmd Intratumoral versus systemic: different.

@jasonwilliamsmd @drgoodyear our supppsed competition: "The problem with the CD40/CD40L (CD154) signaling pathway is its dual role: while essential for normal immune system function, its chronic or over-activated state drives severe inflammatory and autoimmune diseases" 🤔

@therealAlPrince @jasonwilliamsmd We rarely use chemo if ever at all.

@jasonwilliamsmd @drgoodyear unpack this chemo cocktail pushers

The discussion was surrounding its indication. We stack therapies that engage and activate the immune system and no one drug does that. On CD40 front: I encourage you to read following: Juan C. Osorio, David A. Knorr, Polina Weitzenfeld, Lucas Blanchard, Ning Yao, Maria Baez, Carlo Sevilla, Meghan DiLillo, Jahan Rahman, Ved P. Sharma, Jacqueline Bromberg, Michael A. Postow, Charlotte Ariyan, Mark E. Robson, Jeffrey V. Ravetch. Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. Cancer Cell, 2025; 43 (10): 1902 DOI: 10.1016/j.ccell.2025.07.013

@jasonwilliamsmd @drgoodyear my god, it's scary how uninformed these oncologists are. dr pat has NEVER advocated Anktiva as a stand alone drug. have these guys ever even watched a presentation discussing the "triangle offense?" cd40? the one that he then admitted was causing problems??

@tylerbowyer Dialogue versus derogatory degradation. Even in the space of medicine it is rare to find physicians willing to engage in dialogue.

The Charlie Kirk Way!

@FindMentalEase @jasonwilliamsmd Join us on the live stream.

@jasonwilliamsmd @drgoodyear I keep hearing about Anktiva. In simple terms, what is it and why does it matter?

@pumpmikeypump @jasonwilliamsmd Well said

@jasonwilliamsmd @drgoodyear No drug works for everything so context always matters.

@meditatedheal @jasonwilliamsmd Getting ahead of the science. It absolutely is a big addition, like immune check point inhibitors, but they don’t achieve remissions in 100%.

@jasonwilliamsmd @drgoodyear Dr. Soon-Shiong said Anktiva could cure cancer and treat all cancers. Is that realistic, or is that getting ahead of the science?

@HealthoftheMan @jasonwilliamsmd Have to maintain the dialogue within the body of science. It is ok to speak of all the research but identify the positives, negatives, and limitations.

@jasonwilliamsmd @drgoodyear The FDA just issued a warning letter about those claims. What does a warning like that actually mean for patients and for the drug itself?